Interleukin-62/lymphocyte as a proposed predictive index for COVID-19 patients treated with monoclonal antibodies

Rotundo, Salvatore; Borelli, Massimo; Scaglione, Vincenzo; Lionello, Rosaria; Biamonte, Flavia; Olivadese, Vincenzo; Quirino, Angela; Matera, Giovanni; Costanzo, Francesco; Russo, Alessandro; Trecarichi, Enrico Maria; Torti, Carlo; Serapide, Francesca; Tassone, Bruno; Fusco, Paolo; Davoli, Chiara; Gamba, Valentina La; Morrone, Helen Linda; Berardelli, Lavinia; Tassone, Maria Teresa; Serraino, Riccardo; Costa, Cristina; Foti, Daniela; Longhini, Federico; Bruni, Andrea; Garofalo, Eugenio; Biamonte, Eugenio; Laganà, Domenico; Petullà, Maria; Bertucci, Bernardo; Barreca, Giorgio Settimo; Giancotti, Aida; Gallo, Luigia; Lamberti, Angelo Giuseppe; Liberto, Maria Carla; Marascio, Nadia; Francesco, Adele Emanuela De

doi:10.1007/s10238-023-01081-6

Cited by 2 publications

(2 citation statements)

References 39 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study of patients treated with monoclonal antibodies suggested that the IL6/lymphocyte count ratio is a valuable monitor to identify patients who need more treatment and support both in earlier and later stages of the disease. 22 …”

Section: Discussionmentioning

confidence: 99%

Prognostic value of interleukin‐6 serum levels in hospitalized COVID‐19 patients: A case—control study in Iran

Shojaee,

Rafiee,

Hosseinzadeh

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

IntroductionThe coronavirus pandemic (COVID‐19) is an infectious disease with a high mortality rate that is challenging to treat. Cytokine storm is a crucial factor leading to acute respiratory distress syndrome in COVID‐19 patients. Identifying factors that predict the severity of the disease may be primarily prognostic to guide drug therapy. The objective of this study was to investigate the prognostic role of interleukin 6 (IL‐6) in the hospitalized patients infected with COVID‐19.MethodsThis case‐control study was conducted from October 2019 to April 2020 at Shahid Faqihi hospital in Iran. Fifty hospitalized COVID‐19 patients and 50 healthy individuals were included while controlling demographics and comorbidities. IL‐6 serum levels were measured and compared based on demographic characteristics (age, sex) and comorbidities in the case and control groups. Spearman rank correlation coefficient was also used to analyze the correlations between IL‐6 levels and lung involvement in COVID‐19 patients. Moreover, some laboratory parameters were compared based on the percentage of lung involvement.ResultsThe level of IL‐6 in the case group was significantly higher than the control (p ˂ 0.001). We observed a positive and significant correlation between the level of IL‐6 and the severity of lung involvement (r = 0.0.79, p < 0.01). The median level of IL‐6 in patients who showed more than 75% lung involvement was 573 (IQR = 320−850).ConclusionAvailable evidence suggests that high levels of IL‐6 are associated with the severity of COVID‐19. According to the results, it could be proposed that inhibition of IL‐6 might be a target for therapeutic managements to reduce mortality in the patients with COVID‐19.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of interleukin‐6 serum levels in hospitalized COVID‐19 patients: A case—control study in Iran

Shojaee,

Rafiee,

Hosseinzadeh

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…Therefore, not only geographical differences reflecting heterogenicity in demographic and clinical characteristics of patients (5), but also the pandemic waves are an important factor which may have an impact on patient prognosis. For these reasons, prognostic scores (including clinical variables, radiological features and biomarkers) that were elaborated in the previous waves (35)(36)(37)(38)(39)(40) may change their accuracy across different pandemic waves and should be re-evaluated in the current epidemiological scenario.…”

Section: Figurementioning

confidence: 99%

Evolution of in-hospital patient characteristics and predictors of death in the COVID-19 pandemic across four waves: are they moving targets with implications for patient care?

Trecarichi,

Olivadese,

Davoli

et al. 2024

Front. Public Health

Self Cite

View full text Add to dashboard Cite

ObjectivesThe aim of this work was to study characteristics, outcomes and predictors of all-cause death in inpatients with SARS-CoV-2 infection across the pandemic waves in one large teaching hospital in Italy to optimize disease management.MethodsAll patients with SARS-CoV-2 infection admitted to our center from March 2020 to June 2022 were included in this retrospective observational cohort study. Both descriptive and regression tree analyses were applied to identify factors influencing all-cause mortality.Results527 patients were included in the study (65.3% with moderate and 34.7% with severe COVID-19). Significant evolutions of patient characteristics were found, and mortality increased in the last wave with respect to the third wave notwithstanding vaccination. Regression tree analysis showed that in-patients with severe COVID-19 had the greatest mortality across all waves, especially the older adults, while prognosis depended on the pandemic waves in patients with moderate COVID-19: during the first wave, dyspnea was the main predictor, while chronic kidney disease emerged as determinant factor afterwards.ConclusionPatients with severe COVID-19, especially the older adults during all waves, as well as those with moderate COVID-19 and concomitant chronic kidney disease during the most recent waves require more attention for monitoring and care. Therefore, our study drives attention towards the importance of co-morbidities and their clinical impact in patients with COVID-19 admitted to hospital, indicating that the healthcare system should adapt to the evolving features of the epidemic.

show abstract

Interleukin-62/lymphocyte as a proposed predictive index for COVID-19 patients treated with monoclonal antibodies

Cited by 2 publications

References 39 publications

Prognostic value of interleukin‐6 serum levels in hospitalized COVID‐19 patients: A case—control study in Iran

Prognostic value of interleukin‐6 serum levels in hospitalized COVID‐19 patients: A case—control study in Iran

Evolution of in-hospital patient characteristics and predictors of death in the COVID-19 pandemic across four waves: are they moving targets with implications for patient care?

Contact Info

Product

Resources

About